• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤维蛋白肽B释放速率调节凝血形成速率:一项关于获得性纤维蛋白肽B释放抑制剂的研究。

The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release.

作者信息

Nawarawong W, Wyshock E, Meloni F J, Weitz J, Schmaier A H

机构信息

Department of Medicine, Chiang Mai University, Thailand.

出版信息

Br J Haematol. 1991 Oct;79(2):296-301. doi: 10.1111/j.1365-2141.1991.tb04536.x.

DOI:10.1111/j.1365-2141.1991.tb04536.x
PMID:1958489
Abstract

An asymptomatic 50-year-old male with a gamma globulin paraprotein was found to have prolonged prothrombin time, activated partial thromboplastin time, and thrombin time but a normal reptilase time. The prolonged clotting times were not the result of a factor deficiency because they were not corrected by the addition of normal plasma. Instead, this patient had an antibody that delayed thrombin-mediated fibrinopeptide B release thereby producing an apparent dysfibrinogenaemia. His isolated IgG prolonged the thrombin clotting time of both normal plasma and fibrinogen. Precincubation of his IgG with fibrinopeptide B, but not with fibrinopeptide A or thrombin, decreased its ability to prolong the thrombin clotting time. The patient's purified IgG but not control IgG delayed thrombin-mediated fibrinopeptide B release from fibrinogen without affecting the release of fibrinopeptide A. These studies define a novel, clinically silent dysfibrinogenaemia due to an antibody that delays thrombin-mediated fibrinopeptide B release from fibrinogen thereby markedly prolonging the clotting times.

摘要

一名50岁无症状男性,γ球蛋白副蛋白升高,凝血酶原时间、活化部分凝血活酶时间和凝血酶时间延长,但蝰蛇毒时间正常。凝血时间延长并非因子缺乏所致,因为加入正常血浆后未得到纠正。相反,该患者有一种抗体,可延迟凝血酶介导的纤维蛋白肽B释放,从而导致明显的异常纤维蛋白原血症。其分离出的IgG延长了正常血浆和纤维蛋白原的凝血酶凝血时间。将其IgG与纤维蛋白肽B预温育,而非与纤维蛋白肽A或凝血酶预温育,可降低其延长凝血酶凝血时间的能力。患者纯化的IgG而非对照IgG延迟了凝血酶介导的纤维蛋白肽B从纤维蛋白原的释放,而不影响纤维蛋白肽A的释放。这些研究定义了一种新型的、临床上无症状的异常纤维蛋白原血症,其由一种抗体引起,该抗体延迟了凝血酶介导的纤维蛋白肽B从纤维蛋白原的释放,从而显著延长了凝血时间。

相似文献

1
The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release.纤维蛋白肽B释放速率调节凝血形成速率:一项关于获得性纤维蛋白肽B释放抑制剂的研究。
Br J Haematol. 1991 Oct;79(2):296-301. doi: 10.1111/j.1365-2141.1991.tb04536.x.
2
An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient.
Haematologica. 2007 Feb;92(2):e17-9. doi: 10.3324/haematol.10575.
3
Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.一名复发性血栓形成患者的异常纤维蛋白原血症和狼疮抗凝物
J Lab Clin Med. 1987 Dec;110(6):726-33.
4
Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.异常纤维蛋白原血症,其特征为纤维蛋白单体聚合异常而纤维蛋白肽A释放正常。
Br J Haematol. 1980 Mar;44(3):483-94. doi: 10.1111/j.1365-2141.1980.tb05918.x.
5
An abnormal fibrinogen with delayed fibrinopeptide A release.
Br J Haematol. 1980 Sep;46(1):89-98. doi: 10.1111/j.1365-2141.1980.tb05938.x.
6
The release of small amounts of fibrinopeptide-B (FPB) is of critical importance for the thrombin clotting time.少量纤维蛋白肽-B(FPB)的释放对凝血酶凝血时间至关重要。
Thromb Res. 1986 May 15;42(4):517-26. doi: 10.1016/0049-3848(86)90215-x.
7
Fibrinogen kaiserslautern III: a new case of congenital dysfibrinogenemia with aalpha 16 arg-->cys substitution.纤维蛋白原凯泽斯劳滕III型:一例伴有α16精氨酸→半胱氨酸替代的先天性异常纤维蛋白原血症新病例。
Haemostasis. 2001 Jan-Feb;31(1):12-7. doi: 10.1159/000048039.
8
Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.瓜雷纳斯纤维蛋白原I:一种新型异常纤维蛋白原血症的部分特征,其纤维蛋白肽释放速率改变且聚合受损。
Thromb Res. 1995 Apr 15;78(2):95-106. doi: 10.1016/0049-3848(95)00038-0.
9
Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorrhagic syndrome.
Blood Coagul Fibrinolysis. 1992 Oct;3(5):519-29. doi: 10.1097/00001721-199210000-00002.
10
Fibrinogen Seattle releases half the normal amount of fibrinopeptide B.西雅图纤维蛋白原释放的纤维蛋白肽B量为正常量的一半。
Acta Haematol. 1983;70(4):257-63. doi: 10.1159/000206737.

引用本文的文献

1
Newly diagnosed multiple myeloma with bleeding and coagulation abnormalities caused by a thrombin-inhibiting substance.初诊为多发性骨髓瘤,伴有出血和凝血异常,由一种抑制凝血酶的物质引起。
Int J Hematol. 2024 Dec;120(6):743-749. doi: 10.1007/s12185-024-03849-2. Epub 2024 Sep 18.
2
Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy.病例报告:依维莫司治疗后发现的遗传性异常纤维蛋白原血症
Front Med (Lausanne). 2020 Nov 27;7:591546. doi: 10.3389/fmed.2020.591546. eCollection 2020.
3
Increased thrombosis susceptibility and altered fibrin formation in STAT5-deficient mice.
STAT5 缺陷小鼠血栓形成易感性增加和纤维蛋白形成改变。
Blood. 2010 Dec 16;116(25):5724-33. doi: 10.1182/blood-2010-06-292227. Epub 2010 Sep 7.